FierceBiotechFierceBioResearcherFierceVaccinesFiercePharma   FierceHealthcare
About | Sample | Privacy

Sequoia gains $35M in third round

The Wellcome Trust has led a $35 million third round of venture capital for Sequoia Pharmaceuticals, which has been developing a therapy for drug-resistant HIV. MedImmune Ventures also jumped in as a new investor in the company. Much of the money is earmarked for product development.

- here's the release on the venture round

ALSO: Kleiner Perkins Caufield & Byers Pandemic & Biodefense Fund has added $6 million to Juvaris BioTherapeutics' first venture round. The money goes to pushing its lead vaccine products for influenza and pneumonia indications into clinical trials. Release

More stories about pharmaceuticals   Venture Capital   pandemic   MedImmune   Kleiner Perkins Caufield & Byers   biodefense  

Comments

Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

What is 9 + 1?
To combat spam, please solve the math question above.